Dyne Therapeutics, Inc. (DYN)
| Market Cap | 1.07B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 6.92M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 25 |
| Last Price | $19.40 |
| Previous Close | $20.23 |
| Change ($) | -0.83 |
| Change (%) | -4.10% |
| Day's Open | 20.17 |
| Day's Range | 19.10 - 20.86 |
| Day's Volume | 225,533 |
| 52-Week Range | 15.60 - 32.32 |
News
WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people livi...
- In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 -
About DYN
Dyne Therapeutics, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.
| Industry Pharmaceutical Preparation Manufacturing | IPO Date Sep 17, 2020 |
| CEO Joshua T. Brumm | Employees 36 |
| Stock Exchange NASDAQ | Ticker Symbol DYN |
Analyst Forecasts
According to 4 analysts, the average rating for DYN stock is "Buy." The 12-month stock price forecast is 36.40, which is an increase of 87.63% from the latest price.